

7 December 2021

Company Announcements Office  
ASX Limited

Dear Sir/Madam

**BARD1 Life Sciences Limited**

**Cleansing Notice under section 708A(5) of the Corporations Act 2001 (Cth)**

BARD1 Life Sciences Limited, (ASX:BD1) ("**BARD1**" or "**the Company**") today announced the quotation of four fully paid ordinary shares (**Shares**) via an Appendix 2A – Application for the Listing of Additional Securities. These Shares were issued to the four holders of performance shares after the approval of shareholders of Resolution 5 - Consolidation of Performance Shares at BARD1's AGM held on 29 November 2021.

BARD1 submits this cleansing notice (**Notice**) under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**). These Shares were issued without disclosure under Part 6D.2 of the Corporations Act. As at the date of this Notice, the Company has complied with:

- the provisions of Chapter 2M of the Corporations Act as they apply to BARD1; and
- section 674 of the Corporations Act.

As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

Yours faithfully



Tony Di Pietro  
Company Secretary

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

**COMPANY CONTACTS**

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@bard1.com](mailto:geoff.cumming@bard1.com)  
M +61 417 203 021

**ABOUT BARD1 LIFE SCIENCES LTD**

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).